Regeneration

EQS-News: HeartBeat.bio collaborates with Boehringer Ingelheim to investigate cardiac organoids for the development of new treatments for people with heart diseases

Retrieved on: 
Wednesday, October 5, 2022

The collaboration aims to accelerate development of new therapy options and achieve better outcomes for people with heart diseases.

Key Points: 
  • The collaboration aims to accelerate development of new therapy options and achieve better outcomes for people with heart diseases.
  • Boehringer Ingelheim will work with the scientists from HeartBeat.bio to further advance the companys platform using selected reference compounds from Boehringer Ingelheims research and development programs.
  • [1] Existing cardiac safety screening models, such as cardiomyocytes, are limited in predictability as they are not able to sufficiently recapitulate human heart physiology.
  • HeartBeat.bios heart organoids are stem-cell derived 3D cell culture systems, which mimic the human heart physiology in a totally new way.

EnerPure Inc. Announces MoU for Alberta Regeneration Unit

Retrieved on: 
Tuesday, October 4, 2022

Winnipeg, MB, Oct. 04, 2022 (GLOBE NEWSWIRE) --

Key Points: 
  • Gold Fuels is an Indigenous partnership with a strong network of business relationships across Alberta and Saskatchewan.
  • Under the terms of the MoU, EnerPure will manage the full development, construction, and operations of the regeneration unit and Gold Fuels will provide financing for all capital costs.
  • The micro-regeneration unit is targeted to be fully operational in 2024.
  • EnerPure is a Manitoba cleantech company founded on the idea that waste oil recycling should be accessible to all communities.

EQS-News: Immunic to Participate in Scientific and Industry Conferences in October

Retrieved on: 
Tuesday, October 4, 2022

The poster presentation will be accessible on the Events and Presentations section of Immunic's website at: https://ir.imux.com/events-and-presentations .

Key Points: 
  • The poster presentation will be accessible on the Events and Presentations section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Members of Immunics business development and investor relations teams will attend this conference in Leipzig, Germany and participate in partnering activities.
  • Examples of such statements include, but are not limited to, statements relating to managements and employees participation in scientific and industry conferences.
  • Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Immunic to Participate in Scientific and Industry Conferences in October

Retrieved on: 
Tuesday, October 4, 2022

Members of Immunic's business development and investor relations teams will attend this conference in Leipzig, Germany and participate in partnering activities.

Key Points: 
  • Members of Immunic's business development and investor relations teams will attend this conference in Leipzig, Germany and participate in partnering activities.
  • Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in scientific and industry conferences.
  • Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.
  • Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Innovation and Distinctive Design Underscored: Kia Canada introduces second-generation 2023 Niro

Retrieved on: 
Monday, October 3, 2022

Perfectly timed for growth in this segment, Niro has enjoyed tremendous success in Canada for those looking for an environmentally conscious vehicle.

Key Points: 
  • Perfectly timed for growth in this segment, Niro has enjoyed tremendous success in Canada for those looking for an environmentally conscious vehicle.
  • Inside and out, the 2023 Niro features bold design inspired by the Opposites United philosophy Joy for Reason.
  • Just like the Kia Telluride and recently introduced all-new Sportage, with their unmistakable headlight design, the Niro is no exception.
  • Kia Canada Inc., founded in 1999, is a subsidiary of Kia Corporation based in Seoul, South Korea.

EnerPure Inc. Announces Private Placement to Raise $10 Million

Retrieved on: 
Monday, October 3, 2022

Todd Habicht, CEO and Founder commented: The continued progress of EnerPure has positioned us well for a successful capital raise and we are eager to capitalize on this exciting next phase of growth.

Key Points: 
  • Todd Habicht, CEO and Founder commented: The continued progress of EnerPure has positioned us well for a successful capital raise and we are eager to capitalize on this exciting next phase of growth.
  • We are ready to begin rolling out our technology across North America and these funds will allow us to aggressively implement our plans.
  • EnerPure is a Manitoba cleantech company founded on the idea that waste oil recycling should be accessible to all communities.
  • EnerPure is pleased to have received funding and support from Sustainable Development Technology Canada (SDTC).

CollPlant to present at the Dawson James Small Cap Growth Conference on October 12

Retrieved on: 
Monday, October 3, 2022

Mr. Rotem's presentation will take place on Wednesday, October 12th at 14:00-14:25 PM ET.

Key Points: 
  • Mr. Rotem's presentation will take place on Wednesday, October 12th at 14:00-14:25 PM ET.
  • Investors attending the event may request a one-on-one meeting through the conference coordinators.
  • CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics.
  • The Company's products are based on its recombinant human collagen produced with CollPlant's proprietary plant based genetic engineering technology.

GREENFIELD GLOBAL TRIPLES PRODUCTION CAPACITY FOR ETHANOL BLENDS WITH WATER-FOR-INJECTION TO MEET FAST-GROWING BIOPHARMA DEMAND

Retrieved on: 
Thursday, September 29, 2022

Brookfield, Connecticut, Sept. 29, 2022 (GLOBE NEWSWIRE) -- To meet the increased demand from biopharma customers, Greenfield Global is tripling its production capacity for ethanol blends with water-for-injection (WFI) at its Brookfield, Connecticut plant from a 2,000 gallon tank to a total capacity just shy of 6,000 gallons.

Key Points: 
  • Brookfield, Connecticut, Sept. 29, 2022 (GLOBE NEWSWIRE) -- To meet the increased demand from biopharma customers, Greenfield Global is tripling its production capacity for ethanol blends with water-for-injection (WFI) at its Brookfield, Connecticut plant from a 2,000 gallon tank to a total capacity just shy of 6,000 gallons.
  • Greenfields increased capacity provides greater confidence in supply chain security and increases production lead times for the laboratories, medical device manufacturers, and both large and small molecule pharmaceutical companies served around the globe.
  • Our chemists and engineers are continually adapting and adding capabilities without compromising quality, said Frank Richards, Executive Vice President and Managing Director, Specialty Chemicals & Ingredients at Greenfield Global.
  • Greenfield Global Inc. is the largest privately owned high-purity alcohol company in North America.

Australia Regenerative Medicine Market Report 2022: Expanding Healthcare Infrastructure and Increasing Evolution in the Pharmaceutical Sector Drives Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022

Australia regenerative medicine market is projected to grow at a significant CAGR during the forecast period, 2023-2027.

Key Points: 
  • Australia regenerative medicine market is projected to grow at a significant CAGR during the forecast period, 2023-2027.
  • The market growth can be attributed to the expanding healthcare infrastructure and increasing evolution in the pharmaceutical sector to design advanced drugs.
  • Besides, increasing research & development activities to advance pharmaceutical products and find curative therapies for unknown diseases are contributing to the growth of Australia regenerative medicine market.
  • In this report, Australia regenerative medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)

Retrieved on: 
Tuesday, September 27, 2022

ROCKVILLE, Md., Sept. 27, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting today that its U.S. joint venture (JV) partner and licensee, HLB Therapeutics (HLBT), has announced that it submitted a protocol for its second phase 3 clinical trial (SEER-2) to the U.S. FDA on September 26th, evaluating RGN-259 as a treatment for neurotrophic keratopathy (NK).  NK is being developed by ReGenTree, a U.S. joint venture company between RegeneRx Biopharmaceuticals, Inc. and HLB Therapeutics.  The following is the text of HLB's press release with a few edits and modifications for clarification.

Key Points: 
  • NK is being developed by ReGenTree, a U.S. joint venture company between RegeneRx Biopharmaceuticals, Inc. and HLB Therapeutics.
  • The following is the text of HLB's press release with a few edits and modifications for clarification.
  • In the SEER-2 and SEER-3 studies, approximately 70 patients will be recruited in each study to evaluate efficacy, in particular complete healing after 4 weeks treatment.
  • RGN-259 is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.